you are here:Home » Events » FlandersBio-Roche Diagnostics Partner Day 2017: Next Generation Sequencing and Immuno-Histochemistry
in het nederlandsin english
FlandersBio organises events that provide opportunities for networking and tapping into the knowledge and expertise of all the life sciences companies. We also keep you informed about other interesting life sciences events. You can also send us your life sciences event.
FlandersBio organiseert seminaries en workshops om het netwerken te bevorderen. Op die manier delen bedrijven gespecialiseerd in biowetenschappen ook hun knowhow en expertise met elkaar. Verder houden we u ook op de hoogte van andere interessante evenementen die gelinkt zijn met de biowetenschappen. Stuur gerust ons gerust jouw evenement door.
FlandersBio-Roche Diagnostics Partner Day 2017: Next Generation Sequencing and Immuno-Histochemistry
Thursday, March 30, 2017 (12:00h - 18:30h)
FlandersBio and Roche Diagnostics are happy to welcome you on their second joint Partner Day. This year’s edition will highlight innovation in the different steps in a next generation sequencing workflow starting from liquid biopsies. Examples will be given of critical steps and new tools to support important outcome-improving choices to be made by you as a researcher, routine operator, technology decision maker, purchaser, business developer in biopharma, academics, hospital labs and service provider.
One breakout session will focus on how to raise the quality of your NGS results at the different phases of sample preparation (cfDNA), target enrichment, sequencing and data analysis: both on a technological level as by best practices and concrete examples. A second breakout session will emphasize the use of biomarkers and companion diagnostics for immuno-histochemistry. Further topics are a.o. the benefits of simulation processes and combining the information from both next-generation sequencing and immunohistochemistry in clinical trials.
The afternoon will be closed by a vivid debate on the implementation of cfDNA for NGSin pharma development, clinical trials and finally a routine clinical flow. It will further address the strength of combining the information from NGS and tissue analysis. We warmly encourage you to ask your questions to a knowledgeable panel with stakeholders from all relevant parties during this panel discussion!
Who should attend? All Dx stakeholders active in R&D, QC, BD and translational research.
Why? Learn everything about implementing ctDNA, new technologies for target enrichment and CDx-developments with IHC! Make new contacts in the Dx world in pharma, biotech, service providers, CRO's and academics in Flanders and beyond.
The full programme can be found below.
40 EUR for FlandersBio members and Roche Diagnostics customers
80 EUR for non-FlandersBio members and non-Roche Diagnostics customers
Please register before 23/03/2017 using the form below.
This Partner Day reflects the catalyzing role of FlandersBio and Roche Diagnostics to promote knowledge transfer amongst all players in the personalized healthcare field and to better understand the needs of the Dx ecosystem in Flanders and beyond.
With the support of:
FlandersBio is happy to announce its first “Diagnostics (Dx) of the Future Brainstorming Day“ which results from a new strategic alliance between FlandersBio and Roche Diagnostics. The event will take place on October 20th 2015 (12:00-6:00 PM) at Maison Grand Place in Brussels.
International keynotes on high end evolutions in early discovery, talks on the newest trends in tissue diagnostics and next generation sequencing (NGS) will be alternated by a debate on the means of financing companion diagnostics and their medico-economical impacts and by a brainstorming session on how to implement NGS in routine diagnostics.
Who should attend? All Dx stakeholders active in R&D, QC and BD in translational research.
Lunch and networking moments will allow you to make new contacts in the Dx world in pharma, biotech, CRO and academics in Flanders and beyond.
Please mark your calendar! High-level agenda will be sent soon.
Registration is already possible through this link.
For any further information, please do not hesitate to contact us
14.20 Pathology lab activities, on the way to the future Nicole Bordier, Pathology Team Leader, Galderma (France)
14.40 Life saving diagnostics and precision medicines for cancer patients: it takes two to tango. Lessons from the (evolving) story of ALK in NSCLC Ludwig Van den Hove, Medical Advisor Oncology, Pfizer
15.00 Coffee Break
15.30 Cost-Effective Innovation Towards Faster (Personalized) Diagnosis: The Role of Simulation Thierry Marchal, Industry Director Healthcare, Ansys
15.50 The development of a new efficient way to fight cancer by combining innovative sequencing and pathology technologies with clinical knowledge in a patient-centric set-up Jean-François Laes, CTO, OncoDNA
16.10 The view of Europe on the use of cfDNA in liquid biopsies in clinical trials Dieter Deforce, Scientific Committee Member and Expert, European Medicines Agency
16.30 Panel Discussion: How to combine tissue analysis and ctDNA NGS in pharma development & clinical trials? How to integrate the different sample types, the clinical trial processes, the data and the registration and reimbursement dossiers? Dieter Deforce / Nicole Bordier / Jean-François Laes / Joeri Van Op den bosch
Moderated by: Benedikt Van Nieuwenhove, Managing Director, ECCRT